Norwich adds small-scale manufacuting capacity for formulators

By Gareth Macdonald

- Last updated on GMT

Norwich Pharmaceuticals has added development-stage drug production to its offering with new dedicated non-GMP capacity at its New York plant.

The expansion includes a range of small-scale granulation, separation and milling units that, the US contract manufacturing organisation (CMO) claims, make testing the feasibility of developmental formulations a quicker, more efficient process.

Robert O'Connor, head of the new unit, "With these new capabilities, we are now able to move directly from initial product development into our existing GMP pilot plant for process optimization, clinical supply manufacturing and submission batch production​."

Company president Chris Calhoun echoed this, explaining that the expansion “fills a significant unmet need for customers who are seeking a complete range of services from a contract provider​.”

The move also marks a change in Norwich’s growth efforts which have, in recent months​, focused around building in the drug trial space with the establishment of contract research arm in India.

When that project was announced in April Norwich said that, in addition to providing research services to external client, its parent company, generic drugmaker Alvogen, would also benefit from the clinical capabilities.

This policy inter-organisation cooperation is also likely to extend to the small-scale manufacturing capacity Norwich has added, given that formulation is an import part of any non-branded drugmaker's business.

Further support for this idea comes from comments made by Alvogen CEO Doug Drysdale at the opening of the firm's new complex generics R&D centre in Pine Brook, New Jersey in June.

Drysdale said the centre will help the firm make the most of first-to-file opportunities, adding that: “Our expanded internal capabilities form an important cornerstone of our targeted development strategy.”

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us


View more